PDF icon Download PDF
J Neurol Surg B Skull Base 2024; 85(06): 650-658
DOI: 10.1055/s-0043-1774792
Original Article

Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits

Bledi C. Brahimaj
1   Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Kevin J. Contrera 
2   Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Franco Rubino
1   Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Romulo Andrade de Almeida
1   Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Renata Ferrarotto
3   Department of Thoracic—Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Jack Phan
4   Department of Head and Neck Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Shirley Y. Su
2   Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Ehab Y. Hanna
2   Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Franco DeMonte
1   Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
,
Shaan M. Raza
1   Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Texas, United States
› Author Affiliations
› Further Information
Also available atMedOne
   Permissions and Reprints
Preview

Abstract

Objective The aim of this study was to investigate the safety of induction chemotherapy (IC) for patients with sinonasal malignancies with brain invasion or a neurological deficit.

Methods We conducted a retrospective analysis of patients who underwent IC for sinonasal malignancies with intracranial invasion or a neurological deficit at a single tertiary cancer center from 1992 to 2020.

Results In total, 460 patients with sinonasal malignancies were included in the study. Of the patients reviewed, 341 underwent IC and within this group 40 had brain invasion (BI) and 31 had a neurological deficit (ND) at presentation. The most prevalent malignancy was sinonasal undifferentiated carcinoma (BI 40%, ND 41.9%), followed by esthesioneuroblastoma (BI 27.5%, ND 9.7%). All tumors were stage T4 with the majority lacking nodal metastases (BI N0: 72.5%, ND N0: 77.5%). All patients completed at least two cycles of IC. Partial or complete response to IC was seen in 80% of BI and 71% of ND patients. No patients had cessation of treatment due to neurologic decline and none required urgent surgery. Five patients (12.5%) with BI and 2 (6.5%) with ND had interruption of IC for reasons other than neurological decline. In patients with ND, IC led to improvement of 54.5% NDs.

Conclusion In patients with sinonasal malignancies with BI or ND who underwent IC, no patients had cessation of treatment due to neurologic decline. In contrast, most patients had improvement of neurologic symptoms with IC. IC was safely administered without interruption due to neurological decline or symptom progression.

Keywords

induction chemotherapy - sinonasal - esthesioneuroblastoma - squamous cell carcinoma - sinonasal undifferentiated carcinoma - brain invasion - neurological deficits

Previous Presentation

Podium presentation at the North American Skull Base Society Annual Meeting, Tampa Florida, United States, February 17, 2023.




Publication History

Received: 01 May 2023

Accepted: 17 August 2023

Article published online:
25 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany